on Innoscripta AG (isin : DE000A40QVM8)
Innoscripta SE Enters US Market Addressing New IRS R&D Documentation Needs
innoscripta SE has marked a successful entry into the US market, securing key customers shortly after its launch. The company, based in Tutzing, has attracted an international technology group from New York and a Minnesota-based clinical trial software provider. This expansion aligns with innoscripta's strategy to grow its international presence.
The urgency for structured R&D documentation is heightened due to new IRS requirements under Form 6765, Section G. This necessitates detailed reporting of research expenditures. innoscripta's Clusterix software offers a solution, providing transparent and detailed project documentation.
The US remains a leading R&D hub, with companies investing over EUR 570 billion in 2025. innoscripta aims to significantly increase its international revenue share by leveraging this vast market potential.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Innoscripta AG news